Hao Dang^*

Oncologie, Vol.22, No.1, pp. 35-42, 2020, DOI:10.32604/oncologie.2020.012485

Abstract This study aimed to explore the expression and diagnostic performance of miR-586 and miR-493 in patients with osteosarcoma. We enrolled 63 patients with osteosarcoma treated between May 2016 and May 2019 as the experimental group and 55 healthy volunteers who underwent physical examination during the same period as the control group. We detected miR-586 and miR-493 expression in serum, normal bone tissue, and tumor samples. We also evaluated the relationship between clinical indicators and the miR-586 and miR-493 expression levels. The correlation between the serum and osteosarcoma tissue expression of miR-586 and miR-493 was examined… More >

Jingjing He^1,2, Lingyi Zhang², Dan Guo³, Xingwen Han⁴, Hui Zhang⁵, Liang Wang², Youcheng Zhang^1,*

Oncologie, Vol.22, No.1, pp. 1-12, 2020, DOI:10.32604/oncologie.2020.012436

Abstract Hepatocellular carcinoma (HCC) ranks the sixth place of most common cancers. Meanwhile, it is the tertiary mortality cause of cancer. There is no effective therapeutic method to prevent and treat the liver cancer. Sinomenine is a kind of Chinese traditional medicine herbal, it is reported that it can inhibit the viability of several cancer cells. The study is to explore whether sinomenine is also able to inhibit the cell viability of HCC and its potential mechanism. The IC50 of sinomenine in BEL-7402 cells was 5.351 mmol/L, and the IC50 of sinomenine in SMMC-7721 cells was… More >